

# Endometriosis Affects Oocyte Morphology in Intracytoplasmic Sperm Injection Cycles

Edson Borges Jr.<sup>1</sup>, Daniela P. A. F. Braga<sup>1,2</sup>, Amanda S. Setti<sup>3</sup>, Livia S. Vingris<sup>1</sup>, Rita Cassia S. Figueira<sup>1</sup>, Assumpto Iaconelli Jr<sup>1</sup>

<sup>1</sup>Fertility – Medical Group – São Paulo – Brasil

<sup>2</sup>Disciplina de Urologia, Área de Reprodução Humana, Dept<sup>o</sup> de Cirurgia, Universidade Federal de São Paulo

<sup>3</sup>Instituto Sapientiae – Centro de Estudos e Pesquisa em Reprodução Assistida

## ABSTRACT

**Objective:** To identify associations between presence of endometriosis and oocyte defects, embryo developmental potential, and cycle outcomes.

**Methods:** This study looked into the impact of endometriosis on oocyte and embryo quality, and blastocyst formation probability. Endometriosis was also correlated with cycle characteristics. In order to avoid age-related bias, in the first analysis only patients aged 36 years or younger were included, and the cycles were split into endometriosis infertility cycles (n=431; 3172 oocytes) and other cycles (n=2510; 24480 oocytes).

**Results:** The number of retrieved oocytes (10.6±21.2 vs. 14.6±21.1,  $P<0.001$ ), oocyte yield (68.1±20.0% vs. 70.6±19.6%,  $P=0.015$ ), and embryos obtained (6.1±4.43 vs. 7.8±5.12,  $P<0.001$ ) were lower among patients with endometriosis. Implantation rates (28.1%±38.9% vs. 33.9±42.7,  $P<0.001$ ) were lower among patients with endometriosis, but fertilization, pregnancy, miscarriage and cycle cancelation rates were not different. There was a significant increase in the incidence of extra-cytoplasmic, but not intra-cytoplasmic, oocyte defects among patients with endometriosis. The quality of embryos (45.3% vs. 47.3%,  $P=0.037$ ) collected from patients with endometriosis was lower, but blastocyst formation rates were unaltered.

**Conclusions:** A possible explanation for the lower implantation rates seen in patients with endometriosis is the poorer quality of the oocytes and embryos observed in this group of patients.

**Keywords:** Endometriosis, ICSI, Oocytes, Embryos, Implantation

## INTRODUCTION

It has been suggested that endometriosis is a heterogeneous disease characterized by the presence of endometrial-type cells outside the uterine cavity (Vercellini *et al.* 2013).

The pathogenesis of endometriosis is still unclear, but retrograde menstruation (Giudice & Kao, 2004), altered immunity (Steele *et al.*, 1984), coelomic metaplasia, metastatic spread (Macer & Taylor, 2012), stem cell and genetic origins have been listed as possible causes (Chan *et al.*, 2004; Du & Taylor, 2007; Zanatta *et al.*, 2010).

Endometriosis patients may be asymptomatic or present a wide variety of symptoms, ranging from pelvic pain to infertility (Burns & Schenken, 1999). Infertility may be present in 30-50% of the individuals with endometriosis (Verkauf, 1987) for unclear reasons. Fecundity is reduced due to mechanical disruptions in cases of advanced pelvic endometriosis with extensive peritoneal adhesions and consequent pelvic anatomy distortions (Holoch & Lessey, 2010).

Substances produced by the implant or adjacent tissues such as prostaglandins, cytokines and growth factors

have been listed as possible etiological factors of endometriosis-associated infertility (Olive & Pritts, 2001). Assisted reproductive technologies (ART) constitute a valid alternative for patients with endometriosis-associated infertility (Opoien *et al.*, 2012; Dong *et al.*, 2013).

More than a third of the women offered ART reportedly have endometriosis (Verkauf, 1987); however, studies on the outcome of ART for endometriosis-associated infertility have described conflicting results. Although some studies have reported decreased success rates in minimal/mild endometriosis when compared with non-endometriosis groups (Wardle *et al.*, 1985; Matson & Yovich, 1986; Simon *et al.*, 1994; Arici *et al.*, 1996), other authors have failed to report differences between these groups (Inoue *et al.*, 1992; Olivennes *et al.*, 1995; Tanbo *et al.*, 1995; Meden-Vrtovec *et al.*, 2000). For advanced-stage endometriosis, the results are also contradictory with some reports indicating worse (Meden-Vrtovec *et al.*, 2000; Aboulghar *et al.*, 2003; Kuivasaari *et al.*, 2005; Harb *et al.*, 2013) and others describing comparable outcomes after ART (Al-Fadhli *et al.*, 2006; Gupta *et al.*, 2006; Matalliotakis *et al.*, 2007).

Studies supporting the poor outcome theory suggest that endometriosis-associated infertility patients offered ART present poor ovarian response (Al-Azemi *et al.*, 2000; Matalliotakis *et al.*, 2007; Lin *et al.*, 2010), lower fertilization rates (Gupta *et al.*, 2006; Lin *et al.*, 2010), decreased endometrial receptivity (Giudice & Kao, 2004; Holoch & Lessey, 2010), and poor implantation rates (Harb *et al.*, 2013). It has also been suggested that oocyte and embryo quality (Brizek *et al.*, 1995; Pellicer *et al.*, 1995; Garrido *et al.*, 2000; Ota *et al.*, 2000; Ota *et al.*, 2002; Goud *et al.*, 2014) may be compromised in patients with endometriosis-associated infertility. It has also been reported that the incidence of aneuploidy is significantly higher in patients with endometriosis (Gianaroli *et al.*, 2010).

To our knowledge, the effect of endometriosis-associated infertility on oocyte quality, specifically related to intra- and extra-cytoplasmic defects, has not been investigated yet. Therefore, the goal of this study was to identify associations between the presence of endometriosis and oocyte defects, embryo developmental potential, and cycle outcomes.

## MATERIALS AND METHODS

### Study Design

This study included oocytes obtained from patients undergoing Intracytoplasmic sperm injection (ICSI) cycles at a private assisted fertilization center between January 2005 and May 2014. The patients were distributed into groups according to the cause of infertility. In order to avoid age bias, only females aged 36 years or younger were included and the cycles were split into endometriosis infertility cycles (n=431; 3172 oocytes) and other cycles (n=2510 cycles; 24480 oocytes).

The endometriosis group included individuals with moderate and severe endometriosis (ASRM III–IV).

The oocytes were evaluated immediately before sperm injection, and the embryos were evaluated 16–18 hours after ICSI and on days two, three and five of development. The influence of the presence of endometriosis on oocyte quality, embryo quality at the cleavage stage (day three), and the rate of blastocyst formation were evaluated. Moreover, the presence of endometriosis was correlated with cycle characteristics and clinical outcomes, such as: (i) number of aspirated follicles; (ii) number of obtained oocytes; (iii) oocyte yield, (iv) mature (MII) oocyte rate, (v) fertilization rate; (vi) clinical pregnancy rate; (vii) miscarriage rate, and (viii) implantation rate.

Patients provided written consent and agreed to share the outcomes of their cycles for research purposes. The local institutional review board approved the study.

### Controlled ovarian stimulation

Controlled ovarian stimulation (COS) was achieved by pituitary blockage using a GnRH antagonist (Cetrotide; Serono, Geneva, Switzerland); ovarian stimulation was performed using recombinant FSH (Gonal-F; Serono, Geneva, Switzerland).

Follicular growth was monitored using transvaginal ultrasound examination starting on day four of gonadotropin administration. When adequate follicular growth and serum E2 levels were observed, recombinant hCG (Ovidrel; Serono, Geneva, Switzerland) was administered to trigger final follicular maturation. The oocytes were collected 35 hours after hCG administration through transvaginal ultrasound ovum pick-up.

### Preparation of oocytes

The retrieved oocytes were maintained in culture medium (Global® for fertilization, LifeGlobal, Connecticut, USA) with 10% protein supplement (LGPS, LifeGlobal, Connecticut, USA) and covered with paraffin oil (Paraffin oil P.G., LifeGlobal, Connecticut, USA) for two to three hours before the removal of cumulus cells. The surrounding cumulus cells were removed after exposure to a HEPES-buffered medium containing hyaluronidase (80 IU/mL, LifeGlobal, Connecticut, USA). The remaining cumulus cells were mechanically removed by gently pipetting with a hand-drawn Pasteur pipette (Humagen Fertility Diagnostics, Charlottesville, USA).

Oocyte morphology was assessed using an inverted Nikon Diaphot microscope (Eclipse TE 300; Nikon®, Tokyo, Japan) with a Hoffmann modulation contrast system under 400X magnification just before sperm injection (4 hours after retrieval).

Intra-intracytoplasmic dysmorphisms (i) cytoplasmic granularity, (ii) cytoplasmic color, (iii) vacuoles in the ooplasm, (iv) aggregates of smooth endoplasmic reticulum clusters (ERC) in the ooplasm and extra-intracytoplasmic dysmorphisms (v) large perivitelline space (PVS), (vi) PVS granularity, (vii) fragmented polar body (PB), (viii) zona pellucida (ZP) abnormalities and (ix) oocyte shape abnormalities were recorded.

During the ICSI procedure, changes in membrane resistance to sperm injection were also recorded: increased membrane resistance and non-resistant membrane.

Oocytes seen to have released the first polar body were considered mature and were used for ICSI.

### Intracytoplasmic sperm injection

Intracytoplasmic sperm injection was performed in a micro-injection dish prepared with 4  $\mu$ L droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on the heated stage of an inverted microscope at  $37.0 \pm 0.5^\circ\text{C}$ . Approximately 16

hours after ICSI, fertilization was confirmed by the presence of two pronuclei and the extrusion of the second polar body. Embryos were maintained in a 50  $\mu$ L drop of culture medium (Global®, LifeGlobal, Connecticut, USA) with 10% protein supplement and covered with paraffin oil in a humidified atmosphere under 6%  $\text{CO}_2$  at  $37^\circ\text{C}$  for three days.

### Embryo morphology evaluation and embryo transfer

Embryo morphology was assessed 16–18 hours after ICSI and on the mornings of days two, three and five of embryo development using an inverted Nikon Diaphot microscope (Eclipse TE 300; Nikon, Tokyo, Japan) with a Hoffmann modulation contrast system under 400X magnification.

The following parameters were used in the assessment of the morphology of cleavage stage embryos: number of blastomeres, percent fragmentation, variation in blastomere symmetry, presence of multinucleation and defects in the zona pellucida and cytoplasm. High-quality cleavage-stage embryos were defined as those with all of the following characteristics: 8–10 cells on day three, <15% fragmentation, symmetric blastomeres, absence of multinucleation, colorless cytoplasm with moderate granulation and no inclusions, absence of perivitelline space granularity, and absence of zona pellucida dysmorphism. Embryos lacking any of these characteristics were considered to be of low quality.

In the assessment of blastocyst morphology, the embryos were given a numerical score from one to six based on their degree of expansion and hatching status as follows: 1, an early blastocyst with a blastocoel that was less than half of the volume of the embryo; 2, a blastocyst with a blastocoel that was greater than half of the volume of the embryo; 3, a full blastocyst with a blastocoel that completely filled the embryo; 4, an expanded blastocyst; 5, a hatching blastocyst; and 6, a hatched blastocyst. Embryos graded 3, 4, 5, and 6 were considered blastocysts.

The ICM of full, expanded, hatching, and hatched blastocysts was categorized as either high quality (tightly packed with many cells) or low quality (loosely grouped with several or few cells). Similarly, the TE was also categorized as either high quality (many cells forming a cohesive epithelium) or low quality (few cells forming a loose epithelium or very few cells).

One or two embryos were transferred on day five.

### Statistical analyses

The categorical and continuous variables of cycle characteristics, clinical outcomes, and laboratory outcomes were compared between the groups using the Chi-square and Student's *t*-test, respectively. Continuous variables were expressed as the mean value  $\pm$  the standard deviation, and percentages were used for categorical variables.

Statistical significance was attributed to *P*-values of less than five percent ( $P < 0.05$ ). Data analysis was carried out using the Minitab (version 14) Statistical Program.

### RESULTS

Endometriosis patients had fewer aspirated follicles, retrieved oocytes, and obtained embryos, and reduced oocyte yield, and higher total doses of FSH used for COS and greater numbers of transferred embryos; however, the MII oocyte rate did not differ between groups (Table 1).

Concerning cycle outcomes, endometriosis patients had lower fertilization and implantation rates, but their pregnancy, miscarriage, and cycle cancellation rates did not differ from those of healthy subjects (Table 2).

Lab tests showed that patients with endometriosis had a significantly higher incidence of extra-cytoplasmic oocyte defects. In contrast, the incidence of intra-cytoplasmic de-

**Table 1.** Comparison of cycle characteristics between endometriosis cycles and other cycles (control group)

Characteristics	Endometriosis (n=431)	Other (n=2510)	P
Female patient age	33.0 ± 2.54	32.9 ± 3.22	0.165
Aspirated follicles	15.7 ± 12.2	21.0 ± 13.7	< 0.001
Retrieved oocytes	10.6 ± 21.2	14.6 ± 21.1	< 0.001
Oocyte yield	68.1 ± 20.0	70.6 ± 19.6	0.015
MII rate	74.4 ± 20.8	73.9 ± 19.5	0.661
FSH	2327 ± 652	2159 ± 600	< 0.001
Number of embryos	6.1 ± 4.43	7.8 ± 5.12	< 0.001
Transferred embryos	2.2 ± 0.9	1.8 ± 0.9	0.035

Chi-square and Student's t-test. Values expressed as %.

**Table 2.** Comparison of cycle outcomes between endometriosis cycles and other cycles (control group)

Characteristics	Endometriosis (n=431)	Other (n=2510)	P
Fertilization rate	80.5 ± 21.2	79.1 ± 20.0	0.189
Pregnancy rate	36.9	38.5	0.529
Miscarriage rate	16.5	13.6	0.352
Implantation rate	28.1 ± 38.9	33.9 ± 42.7	0.012
Cancelation rate	8.2	8.9	0.600

Chi-square and Student's t-test. Values expressed as %.

facts did not differ between groups (Table 3).

Embryo quality on day three was decreased in the embryos derived from endometriosis patients; however, the presence of endometriosis did not affect the rate of blastocyst formation (Table 4).

## DISCUSSION

The present study looked into the effects of endometriosis-associated infertility on ICSI outcomes. Significantly lower response to COS, lower oocyte quality, lower fertilization rates, lower cleavage stage embryo quality, and lower implantation rates were observed in individuals with endometriosis. Additionally, the pregnancy rates seen in subjects with endometriosis-associated infertility were comparable to the rates observed in cases of infertility for other causes.

These findings are in line with recent reports showing that women with endometriosis undergoing ART have a significantly lower oocyte yield (Singh *et al.*, 2014) and lower fertilization rates (Opoien *et al.*, 2012) in comparison with tubal factor infertility. In accordance with our findings, Opoien *et al.* (2012) also described that in addition to the lower fertilization rate, infertile women with endometriosis have comparable pregnancy rates and live birth rates to women with tubal factor infertility, even after adjusting for confounding factors. In a conflicting finding, Opoien's study reported similar implantation rates between subjects with and without endometriosis.

A previous meta-analysis concluded that patients with endometriosis-associated infertility undergoing IVF respond with significantly lower levels of all markers of the reproductive process, resulting in a pregnancy rate that is almost half of that of women with other indications for IVF. The authors suggested that endometriosis affects not only the receptivity of the endometrium, but also the development of the oocyte and the embryo (Barnhart *et al.*, 2002). More recently, the presence of severe endometriosis was

associated with poor implantation in women undergoing IVF (Harb *et al.*, 2013).

A recently published trial by Filippi *et al.* (2014), investigated whether the presence of endometrioma affected oocyte developmental competence. The study showed that the presence of ovarian endometrioma does not affect oocyte quality. In the study described above, although the authors reported that oocyte morphology was evaluated using an inverted microscope, these data were not described in the results and, apparently, oocyte developmental competence was measured based on the quality of the embryo at the cleavage stage. In our study, oocyte quality was measured based on the presence of individual intra- and extra-cytoplasmic defects. It was noted that when compared to other causes of infertility, endometriosis patients have a higher incidence of extracytoplasmic oocyte defects.

Mature oocytes with apparently normal cytoplasmic organization may exhibit extra-cytoplasmic defects, such as increased perivitelline space, perivitelline debris and/or fragmentation of the first polar body, which may impair the developmental competence of the oocyte (Xia, 1997).

In the present study, in addition to poor oocyte morphology, the fertilization rate was also significantly lower in endometriosis cases. This finding is in accordance with previous studies, showing that poor oocyte morphology is a major determinant of failed or impaired fertilization (Xia, 1997; Javed & Michael, 2012). In addition, a recent meta-analysis published by our group (Setti *et al.*, 2011) showed that the probability of an oocyte becoming fertilized is significantly reduced when extra-cytoplasmic defects such as a large polar body and large perivitelline space are present. Conversely, Balaban & Urman (2006) suggested that extra-cytoplasmic oocyte dysmorphisms should be considered merely as a phenotypic deviation resulting from the heterogeneity of the oocytes retrieved. Nevertheless, as described by Rienzi *et al.* (2010) in a

**Table 3.** Comparison of the presence of oocyte defects between the endometriosis and control groups

	Characteristics	Endometriosis (n=3172)	Other (n=24480)	P
Intra-cytoplasmic defects	Cytoplasmic granularity	14.35	14.25	0.875
	Cytoplasmic color	14.15	13.54	0.336
	Aggregates of smooth ERC	14.98	14.04	0.149
	Vacuoles in the ooplasm	14.70	15.44	0.272
	Retractile bodies	11.22	11.24	0.970
Extra-cytoplasmic defects	ZP abnormalities	22.13	18.27	< 0.001
	PVS granularity	47.91	45.70	0.017
	Large perivitelline space	28.80	24.28	< 0.001
	Fragmented PB	38.15	35.40	0.002
	Shape abnormalities	15.22	13.51	0.007
	Increased membrane resistance	15.29	14.03	0.053
	Non-resistant membrane	16.11	14.46	0.013

ERC: endoplasmic reticulum clusters, ZP: zona pellucida, PB: polar body. Chi-square and Student's t-test. Values expressed as %.

**Table 4.** Comparison of cleavage stage embryo quality and rate of blastocyst formation between the endometriosis and control groups

	Characteristics	Endometriosis (n=3172)	Other (n=24480)	P
Embryo characteristics	High quality embryo on day 3	45.36	47.29	0.037
	Rate of blastocyst formation	51.97	52.49	0.780

Chi-square and Student's t-test. Values expressed as %.

systematic review of the literature on the predictive value of oocyte morphology in IVF, published studies have produced contradicting results and do not entirely support the typical opinion about the features of 'good' and 'bad' oocyte quality and developmental competence.

Interestingly, even though oocyte quality and embryo morphology at the cleavage stage were decreased in the endometriosis group, the rate of blastocyst formation did not differ between groups. Previous studies failed to demonstrate (Graham *et al.*, 2000) or demonstrated a poor correlation (Guerif *et al.*, 2010) between early embryo morphology and blastocyst developmental competence. Conversely, we recently investigated the factors that may contribute to the rate of blastocyst formation and quality, and the data showed that good morphology on day three increased the likelihood by up to three-fold that a blastocyst would be of good quality (Braga *et al.*, 2012).

It could be argued that although the presence of endometriosis may have a detrimental effect on oocyte quality and embryo morphology, after prolonged culture to the blastocyst stage, the embryonic genome has begun to be expressed (Tesarik, 2005). At this stage, sperm-derived genes that influence embryo viability have also been activated.

Our results also showed that implantation – but not pregnancy – rates were also decreased in women with endometriosis undergoing ICSI cycles. Whereas some studies (Bukulmez *et al.*, 2001) fail to show decreased implantation rates in IVF patients with endometriosis, others (Kuivasaari *et al.*, 2005) demonstrate significantly lower implantation

rates in individuals with early and late stages of the disease.

Embryo implantation depends on three critical events: proper embryo development, the acquisition of a receptive endometrium, and proper dialogue between them (Dominguez *et al.*, 2003). Previous reports have discussed a possible role for endometrial receptivity accounting for lower implantation rates in these patients (Rajani *et al.*, 2012), including decreased expression of implantation markers during the window of implantation (Donaghay & Lessey, 2007; Matsuzaki *et al.*, 2010).

The reason why diminished implantation – but not pregnancy – rates were observed in the present trial is unclear. It may be suggested that the pregnancy rate does not consider the number of transferred embryos, which also differed between groups.

In conclusion, this study showed that in addition to a lower number of oocytes, endometriosis patients also had lower implantation rates. The poor implantation rates observed among endometriosis patients may be explained by the reduced quality of their oocytes and embryos, impaired endometrial receptivity, or perhaps both factors combined.

#### CONFLICT OF INTERESTS

No conflict of interest have been declared.

#### Corresponding author:

Daniela Paes de Almeida Ferreira Braga  
Fertility – Medical Group  
Sao Paulo/SP – Brasil  
E-mail: dbraga@fertility.com.br

## REFERENCES

- Aboughar MA, Mansour RT, Serour GI, Al-Inany HG, Aboughar MM. The outcome of in vitro fertilization in advanced endometriosis with previous surgery: a case-controlled study. *Am J Obstet Gynecol.* 2003;188: 371-5.
- Al-Azemi M, Bernal AL, Steele J, Gramsbergen I, Barlow D, Kennedy S. Ovarian response to repeated controlled stimulation in in-vitro fertilization cycles in patients with ovarian endometriosis. *Hum Reprod.* 2000; 15: 72-5.
- Al-Fadhli R, Kelly SM, Tulandi T, Tanr SL. Effects of different stages of endometriosis on the outcome of in vitro fertilization. *J Obstet Gynaecol Can.* 2006; 28: 888-91.
- Arici A, Oral E, Bukulmez O, Duleba A, Olive DL, Jones EE. The effect of endometriosis on implantation: results from the Yale University in vitro fertilization and embryo transfer program. *Fertil Steril.* 1996; 65:603-7.
- Balaban B, Urman B. Effect of oocyte morphology on embryo development and implantation. *Reprod Biomed Online.* 2006; 12: 608-15.
- Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. *Fertil Steril.* 2002; 77: 1148-55.
- Braga DP, Setti AS, de Cassia SFR, Machado RB, Iaconelli A Jr, Borges E Jr. Patient selection criteria for blastocyst transfers in extended embryo culture programs. *J Assist Reprod Genet.* 2012; 29:1357-62.
- Brizek CL, Schlaff S, Pellegrini VA, Frank JB, WorriLOW KC. Increased incidence of aberrant morphological phenotypes in human embryogenesis--an association with endometriosis. *J Assist Reprod Genet.* 1995, 12: 106-12.
- Bukulmez O, Yarali H, Gurgan T. The presence and extent of endometriosis do not effect clinical pregnancy and implantation rates in patients undergoing intracytoplasmic sperm injection. *Eur J Obstet Gynecol Reprod Biol.* 2001; 96:102-7.
- Burns WN, Schenken RS. Pathophysiology of endometriosis-associated infertility. *Clin Obstet Gynecol.* 1999; 42: 586-610.
- Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. *Biol Reprod.* 2004; 70: 1738-50.
- Dominguez F, Pellicer A, Simon C. The chemokine connection: hormonal and embryonic regulation at the human maternal-embryonic interface--a review. *Placenta* 2003; 24: S48-55.
- Donaghay M, Lessey BA. Uterine receptivity: alterations associated with benign gynecological disease. *Semin Reprod Med.* 2007; 25: 461-75.
- Dong X, Liao X, Wang R, Zhang H. The impact of endometriosis on IVF/ICSI outcomes. *Int J Clin Exp Pathol.* 2013; 6: 1911-8.
- Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. *Stem Cells.* 2007; 25: 2082-6.
- Filippi F, Benaglia L, Paffoni A, Restelli L, Vercellini P, Somigliana E, Fedele L. Ovarian endometriomas and oocyte quality: insights from in vitro fertilization cycles. *Fertil Steril.* 2014; 101: 988-93.e1.
- Garrido N, Navarro J, Remohi J, Simon C, Pellicer A. Follicular hormonal environment and embryo quality in women with endometriosis. *Hum Reprod Update.* 2000; 6: 67-74.
- Gianaroli L, Magli MC, Cavallini G, Crippa A, Capoti A, Resta S, Robles F, Ferraretti AP. Predicting aneuploidy in human oocytes: key factors which affect the meiotic process. *Hum Reprod.* 2010; 25: 2374-86.
- Giudice LC, Kao LC. Endometriosis. *Lancet.* 2004; 364:1789-99.
- Goud PT, Goud AP, Joshi N, Puschek E, Diamond MP, Abu-Soud HM. Dynamics of nitric oxide, altered follicular microenvironment, and oocyte quality in women with endometriosis. *Fertil Steril.* 2014; 102: 151-9 e5.
- Graham J, Han T, Porter R, Levy M, Stillman R, Tucker MJ. Day 3 morphology is a poor predictor of blastocyst quality in extended culture. *Fertil Steril.* 2000;74: 495-7.
- Guerif F, Lemseffer M, Leger J, Bidault R, Cadoret V, Chavez C, Gasnier O, Saussereau MH, Royere D. Does early morphology provide additional selection power to blastocyst selection for transfer? *Reprod Biomed Online.* 2010; 21: 510-9.
- Gupta S, Agarwal A, Agarwal R, Loret de Mola JR. Impact of ovarian endometrioma on assisted reproduction outcomes. *Reprod Biomed Online.* 2006; 13: 349-60.
- Harb HM, Gallos ID, Chu J, Harb M, Coomarasamy A. The effect of endometriosis on in vitro fertilisation outcome: a systematic review and meta-analysis. *Bjog.* 2013; 120: 1308-20.
- Holoch KJ, Lessey BA. Endometriosis and infertility. *Clin Obstet Gynecol.* 2010; 53: 429-38.
- Inoue M, Kobayashi Y, Honda I, Awaji H, Fujii A. The impact of endometriosis on the reproductive outcome of infertile patients. *Am J Obstet Gynecol.* 1992; 167: 278-82.
- Javed M, Michael E. Intracytoplasmic Sperm Injection – Factors Affecting Fertilization. Enhancing Success of Assisted Reproduction. In Darwish AMM (ed) Rijeka: InTech; 2012. p 117-44.
- Kuivasaari P, Hippelainen M, Anttila M, Heinonen S. Effect of endometriosis on IVF/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. *Hum Reprod.* 2005; 20: 3130-5.
- Lin XN, Wei ML, Tong XM, Xu WH, Zhou F, Huang QX, Wen GF, Zhang SY. Outcome of in vitro fertilization in endometriosis-associated infertility: a 5-year database cohort study. *Chin Med J (Engl).* 2010; 125: 2688-93.
- Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. *Obstet Gynecol Clin North Am.* 2012; 39: 535-49.
- Mataliotakis IM, Cakmak H, Mahutte N, Fragouli Y, Arici A, Sakkas D. Women with advanced-stage endometriosis and previous surgery respond less well to gonadotropin stimulation, but have similar IVF implantation and delivery rates compared with women with tub-

- al factor infertility. *Fertil Steril*. 2007; 88: 1568-72.
- Matson PL, Yovich JL. The treatment of infertility associated with endometriosis by in vitro fertilization. *Fertil Steril*. 1986; 46: 432-4.
- Matsuzaki S, Darcha C, Maleysson E, Canis M, Mage G. Impaired down-regulation of E-cadherin and beta-catenin protein expression in endometrial epithelial cells in the mid-secretory endometrium of infertile patients with endometriosis. *J Clin Endocrinol Metab*. 2010; 95: 3437-45.
- Meden-Vrtovec H, Tomazevic T, Verdenik I. Infertility treatment by in vitro fertilization in patients with minimal or mild endometriosis. *Clin Exp Obstet Gynecol*. 2000; 27: 191-3.
- Olive DL, Pritts EA. Treatment of endometriosis. *N Engl J Med*. 2001; 345: 266-75.
- Olivennes F, Feldberg D, Liu HC, Cohen J, Moy F, Rosenwaks Z. Endometriosis: a stage by stage analysis--the role of in vitro fertilization. *Fertil Steril*. 1995; 64: 392-8.
- Opoien HK, Fedorcsak P, Omland AK, Abyholm T, Bjercke S, Ertzeid G, Oldereid N, Mellembakken JR, Tanbo T. In vitro fertilization is a successful treatment in endometriosis-associated infertility. *Fertil Steril*. 2012; 97: 912-8.
- Ota H, Igarashi S, Kato N, Tanaka T. Aberrant expression of glutathione peroxidase in eutopic and ectopic endometrium in endometriosis and adenomyosis. *Fertil Steril*. 2000; 74: 313-8.
- Ota H, Igarashi S, Sato N, Tanaka H, Tanaka T. Involvement of catalase in the endometrium of patients with endometriosis and adenomyosis. *Fertil Steril*. 2002; 78: 804-9.
- Pellicer A, Oliveira N, Ruiz A, Remohi J, Simon C. Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. *Hum Reprod*. 1995; 10: 91-7.
- Rienzi L, Vajta G, Ubaldi F. Predictive value of oocyte morphology in human IVF: a systematic review of the literature. *Hum Reprod Update*. 2010; 17: 34-45.
- Setti AS, Figueira RC, Braga DP, Colturato SS, Iaconelli A Jr, Borges E Jr. Relationship between oocyte abnormal morphology and intracytoplasmic sperm injection outcomes: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2011; 159: 364-70.
- Simon C, Gutierrez A, Vidal A, de los Santos MJ, Tarin JJ, Remohi J, Pellicer A. Outcome of patients with endometriosis in assisted reproduction: results from in-vitro fertilization and oocyte donation. *Hum Reprod*. 1994; 9: 725-9.
- Singh N, Lata K, Naha M, Malhotra N, Tiwari A, Vanamail P. Effect of endometriosis on implantation rates when compared to tubal factor in fresh non donor in vitro fertilization cycles. *J Hum Reprod Sci*. 2014; 7: 143-7.
- Steele RW, Dmowski WP, Marmer DJ. Immunologic aspects of human endometriosis. *Am J Reprod Immunol*. 1984; 6: 33-6.
- Tanbo T, Omland A, Dale PO, Abyholm T. In vitro fertilization/embryo transfer in unexplained infertility and minimal peritoneal endometriosis. *Acta Obstet Gynecol Scand*. 1995; 74: 539-43.
- Tesarik J. Paternal effects on cell division in the human preimplantation embryo. *Reprod Biomed Online*. 2005; 10: 370-5.
- Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. *Nat Rev Endocrinol*. 2013; 10: 261-75.
- Verkauf BS. Incidence, symptoms, and signs of endometriosis in fertile and infertile women. *J Fla Med Assoc*. 1987; 74: 671-5.
- Wardle PG, Mitchell, JD, McLaughlin EA, Ray BD, McDermott A, Hull MG. Endometriosis and ovulatory disorder: reduced fertilisation in vitro compared with tubal and unexplained infertility. *Lancet*. 1985; 2: 236-9.
- Xia P. Intracytoplasmic sperm injection: correlation of oocyte grade based on polar body, perivitelline space and cytoplasmic inclusions with fertilization rate and embryo quality. *Hum Reprod*. 1997; 12: 1750-5.
- Zanatta A, Rocha AM, Carvalho FM, Pereira RM, Taylor HS, Motta EL, Baracat EC, Serafini PC. The role of the Hoxa10/HOXA10 gene in the etiology of endometriosis and its related infertility: a review. *J Assist Reprod Genet*. 2010; 27: 701-10.